HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is an
adipose tissue redistribution disorder characterized by subcutaneous adipose tissue …

Lipodystrophy is a common alteration in HIV 1-infected patients under anti-retroviral
treatment. This syndrome is usually associated with peripheral lipoatrophy, central adiposity …

The recent clinical use of potent HIV-1 drugs, including nucleoside reverse transcriptase
inhibitors (NRTIs) and non-peptidic viral protease inhibitors (PIs), and their combinations …

Background The aetiopathogenic bases of HIV-1-/highly active antiretroviral treatment
(HAART)-associated lipodystrophy (HALS) are poorly known, but this syndrome indicates …

Acquired fat redistribution, that is, peripheral fat loss often accompanied by central fat
accumulation in patients with HIV infection is the most common form of lipodystrophy in man …

Human immunodeficiency virus (HIV)-associated adipose redistribution syndrome (HARS) is
a fat accumulation disorder characterized by increases in visceral adipose tissue. Patients …

The use of highly active antiretroviral therapy (HAART) in the treatment of human
immunodeficiency virus has dramatically altered both the landscape of this disease and the …

HIV-associated lipodystrophy syndrome (HALS), comprising metabolic and morphological
alterations, is a known side effect of highly active antiretroviral therapy (HAART). Evidence …

In developed countries, the availability of highly active antiretroviral therapy (HAART) has
contributed to a dramatic decrease in mortality and opportunistic infections associated with …

Background Changes in body fat distribution are a frequent finding in individuals with HIV
infection. Lipoatrophy, or decreased subcutaneous fat in the limbs together with prominent …